Ownership and insider activity for Actuate Therapeutics Inc (ACTU): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Price
| Price | $1.00 |
| Market Cap | $24M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-14 | SCHMITT DANIEL M | M-Exempt | 272,056 | |
| 2026-08-14 | SCHMITT DANIEL M | F-InKind | 120,521 | $122K |
| 2026-08-14 | SCHMITT DANIEL M | M-Exempt | 272,056 | |
| 2026-05-21 | Zabrowski Dan | A-Award | 15,000 | $36K |
| 2026-05-21 | THOMSON TODD S | A-Award | 15,000 | $36K |
| 2026-05-21 | Sawhney Roger | A-Award | 15,000 | $36K |
| 2026-05-21 | RONNEBERG AMY L | A-Award | 15,000 | $36K |
| 2026-05-21 | Keyes Jason A | A-Award | 15,000 | $36K |
| 2026-05-21 | Huber Martin H. Jr. | A-Award | 15,000 | $36K |
| 2026-05-21 | Fletcher Aaron G.L. | A-Award | 15,000 | $36K |
Balance Sheet (10y)
| Year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash & Equivalents | $20.4M | $3.0M | $8.6M | $13.2M |
| Short-term Investments | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Total Current Assets | $20.5M | $3.0M | $9.2M | $13.6M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Total Assets | $20.5M | $3.0M | $9.3M | $14.0M |
| Accounts Payable | $2.1M | $3.4M | $1.9M | $1.5M |
| Short-term Debt | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $4.3M | $6.9M | $8.8M | $5.7M |
| Long-term Debt | $404991 | 0 | 0 | $404991 |
| Total Liabilities | $5.7M | $102.6M | $9.2M | $6.1M |
| Retained Earnings | -$80.3M | -$105.1M | -$132.4M | -$154.6M |
| Total Equity | $14.8M | -$99.6M | $104186 | $7.9M |
| Total Debt | $404991 | 0 | 0 | $404991 |
| Net Debt | -$20.0M | -$3.0M | -$8.6M | -$12.8M |
| Working Capital | $16.1M | -$3.9M | $405397 | $7.9M |
Financial Health
| Debt / Equity | 0.41 |
| Current Ratio | 1.25 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -7.40 |
Profitability
| Return on Equity | -280.51% |
| Return on Invested Capital | -270.08% |
| Return on Assets | -158.36% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALEC · APLT · ELTX · MCRB · MOLN · NKTX · PEPG
Explore sector: Healthcare · Biotechnology
More sections of ACTU: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks